PMID- 27044406
OWN - NLM
STAT- MEDLINE
DCOM- 20171229
LR  - 20191210
IS  - 1432-1750 (Electronic)
IS  - 0341-2040 (Linking)
VI  - 194
IP  - 3
DP  - 2016 Jun
TI  - Clinical Features and Outcomes of Diffuse Alveolar Hemorrhage During 
      Antithrombotic Therapy: A Retrospective Cohort Study.
PG  - 475-81
LID - 10.1007/s00408-016-9873-4 [doi]
AB  - PURPOSE: Antithrombotic therapy could trigger diffuse alveolar hemorrhage (DAH), 
      and there are several case reports of DAH that occurred during antithrombotic 
      therapy (DAH-AT). However, little is known about the clinical features and 
      outcomes of DAH-AT. The purpose of this study was to clarify the features and 
      mortality of DAH-AT. METHODS: 76 consecutive patients with DAH who were admitted 
      to our hospital between January 2003 and April 2014 were retrospectively reviewed 
      to identify the clinical features and outcomes of DAH-AT. The primary outcome was 
      90-day mortality. RESULTS: Of the 76 patients with DAH, 39 patients (51 %) had 
      DAH-AT, and 37 patients (49 %) had DAH that occurred with no antithrombotic 
      therapy (DAH-NAT). Of the patients with DAH-AT, 25 (64 %) were taking aspirin, 14 
      (36 %) were taking warfarin, 5 (13 %) were taking clopidogrel sulfate, and 4 
      (10 %) were taking cilostazol. Pre-existing cardiac disease was present in 23 
      (59 %) DAH-AT cases and 5 (14 %) DAH-NAT cases. Logistic regression analysis was 
      used to assess the effect of antithrombotic therapy on the mortality of DAH 
      patients, and no significant difference in survival was seen with antithrombotic 
      therapy (OR 1.18, 95 % CI 0.38-3.78). CONCLUSIONS: Antithrombotic therapies had 
      no effect on the 90-day mortality of DAH patients.
FAU - Otoshi, T
AU  - Otoshi T
AD  - Department of Respiratory Medicine, Kobe City Medical Center General Hospital, 
      2-1-1 Minatojimaminami-cho, Chuo-ku, Kobe, Hyogo, 650-0047, Japan. 
      takehiro-otoshi19850902@gmail.com.
FAU - Kataoka, Y
AU  - Kataoka Y
AD  - Department of Respiratory Medicine, Hyogo Prefectural Amagasaki General Medical 
      Center, 2-17-77 Higashinaniwa-cho, Amagasaki, Hyogo, 660-8550, Japan.
FAU - Nakagawa, A
AU  - Nakagawa A
AD  - Department of Respiratory Medicine, Kobe City Medical Center General Hospital, 
      2-1-1 Minatojimaminami-cho, Chuo-ku, Kobe, Hyogo, 650-0047, Japan.
FAU - Otsuka, K
AU  - Otsuka K
AD  - Department of Respiratory Medicine, Kobe City Medical Center General Hospital, 
      2-1-1 Minatojimaminami-cho, Chuo-ku, Kobe, Hyogo, 650-0047, Japan.
FAU - Tomii, K
AU  - Tomii K
AD  - Department of Respiratory Medicine, Kobe City Medical Center General Hospital, 
      2-1-1 Minatojimaminami-cho, Chuo-ku, Kobe, Hyogo, 650-0047, Japan.
LA  - eng
PT  - Journal Article
DEP - 20160404
PL  - United States
TA  - Lung
JT  - Lung
JID - 7701875
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Tetrazoles)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - A74586SNO7 (Clopidogrel)
RN  - N7Z035406B (Cilostazol)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aspirin/adverse effects
MH  - Cilostazol
MH  - Clopidogrel
MH  - Connective Tissue Diseases/complications
MH  - Female
MH  - Fibrinolytic Agents/*adverse effects
MH  - Heart Failure/complications
MH  - Hemorrhage/complications/*etiology
MH  - Humans
MH  - Infections/etiology
MH  - Lung Diseases/complications/*etiology
MH  - Male
MH  - Middle Aged
MH  - Neoplasms/complications
MH  - Pneumonia/complications
MH  - Pulmonary Alveoli
MH  - Retrospective Studies
MH  - Survival Rate
MH  - Tetrazoles/adverse effects
MH  - Ticlopidine/adverse effects/analogs & derivatives
MH  - Vasculitis/complications
MH  - Warfarin/adverse effects
OTO - NOTNLM
OT  - Acute respiratory failure
OT  - Antithrombotic therapy
OT  - Critical care medicine
OT  - Diffuse alveolar hemorrhage
EDAT- 2016/04/06 06:00
MHDA- 2017/12/30 06:00
CRDT- 2016/04/06 06:00
PHST- 2015/12/29 00:00 [received]
PHST- 2016/03/24 00:00 [accepted]
PHST- 2016/04/06 06:00 [entrez]
PHST- 2016/04/06 06:00 [pubmed]
PHST- 2017/12/30 06:00 [medline]
AID - 10.1007/s00408-016-9873-4 [pii]
AID - 10.1007/s00408-016-9873-4 [doi]
PST - ppublish
SO  - Lung. 2016 Jun;194(3):475-81. doi: 10.1007/s00408-016-9873-4. Epub 2016 Apr 4.